|1.||Fischman, Alan J: 1 article (01/2012)|
|2.||Beversdorf, David Q: 1 article (01/2012)|
|3.||Bauman, Margaret L: 1 article (01/2012)|
|4.||Bonab, Ali A: 1 article (01/2012)|
|5.||Nordgren, Richard E: 1 article (01/2012)|
|6.||Felopulos, Gretchen J: 1 article (01/2012)|
|7.||Zhou, Feng C: 1 article (01/2012)|
|8.||Dougherty, Darin D: 1 article (01/2012)|
|9.||Weise, Steven B: 1 article (01/2012)|
|10.||Erez, Jonathan: 1 article (01/2010)|
|1.||Alzheimer Disease (Alzheimer's Disease)
06/01/1993 - "In contrast, there was a significant reduction in specific [18F]setoperone binding in the cerebral cortex in patients with Alzheimer's disease relative to control values (temporal, 69%; frontal, 69%; parietal, 55%; temporo-parietal, 54%; occipital cortex, 35%). "
06/01/1993 - "No significant difference was observed between patients with Alzheimer's disease and age-matched controls in the injected mass of setoperone, percentage of unmetabolized [18F]setoperone in plasma, 18F-radioactivity in blood fractions and cerebellar 18F-radioactivity concentration, indicating similar non-specific brain kinetics and metabolism of the radioligand. "
06/01/1993 - "Using [18F]setoperone and positron emission tomography (PET), alterations in serotonergic 5-HT2 receptor binding were studied in cerebral cortex of nine unmedicated patients with probable Alzheimer's disease and 37 healthy controls. "
|2.||Schizophrenia (Dementia Praecox)
01/01/1999 - "The purpose of this study was to investigate this in patients with schizophrenia by means of [18F]setoperone and positron emission tomography (PET) imaging. "
06/01/2000 - "Decreased serotonin 2A receptor densities in neuroleptic-naive patients with schizophrenia: A PET study using [(18)F]setoperone."
01/01/1999 - "Serotonin 5-HT2 receptors in schizophrenia: a PET study using [18F]setoperone in neuroleptic-naive patients and normal subjects."
06/01/2000 - "They used positron emission tomography with [(18)F]setoperone to examine six patients with schizophrenia who had never been given neuroleptics and seven age-matched subjects who did not have schizophrenia. "
05/04/1998 - "To investigate putative abnormalities of cortical 5-HT2A receptor density in schizophrenia, we used positron emission tomography and [18F]setoperone, a high-affinity 5-HT2A receptor radioligand, in 14 neuroleptic-free or -naive schizophrenic patients and in 15 normal controls. "
|3.||Psychotic Disorders (Schizoaffective Disorder)
05/01/2004 - "The authors conducted a PET study to evaluate D(2) occupancy (using [(11)C]raclopride) and 5-HT(2) occupancy (using [(18)F]setoperone) in brain regions of interest in 16 patients with schizophrenia or schizoaffective disorder randomly assigned to receive 40, 80, 120, or 160 mg/day of ziprasidone, which reflected the recommended dose range. "
|4.||Depressive Disorder (Melancholia)
12/01/1996 - "Seventeen stroke patients (mean age 50 +/- 31 yr) with right (n = 9) or left (n = 8) chronic stroke (middle or anterior cerebral artery territory) underwent [18F]setoperone PET and MR imaging. "
12/01/1996 - "Fluorine-18-setoperone PET imaging was used to investigate serotonergic 5-HT2-specific binding in unlesioned cerebral cortex in stroke patients. "
|1.||Serotonin (5 Hydroxytryptamine)
|2.||5-HT2A Serotonin Receptor (5 HT2A Receptor)
|3.||5-HT2 Serotonin Receptors
|9.||Antipsychotic Agents (Antipsychotics)